Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on October 10, 2019. The company is a Delaware corporation with its principal executive offices in Cincinnati, Ohio. Its common stock trades on the Nasdaq Capital Market under the symbol ARPO. The filing reports on a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a clinical trial update and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the issuance of a press release on October 10, 2019, announcing interim results from the Phase 1b clinical trial of the company's topical ocular formulation of AKB-9778 for the treatment of Primary Open Angle Glaucoma. The full details of these results are contained in the attached press release (Exhibit 99.1) and are not summarized within the body of this 8-K text.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent nature of clinical trial results. The primary focus is the disclosure of the interim clinical data as a material event under Item 8.01.
Investor Verification Checklist
- Verify the specific interim results of the Phase 1b trial for AKB-9778 by reviewing the attached press release (Exhibit 99.1).
- Confirm the company name is Aerpio Pharmaceuticals, Inc. (ARPO), as the input metadata referenced Whitehawk Therapeutics, Inc. incorrectly.
- Check subsequent filings for any updates on the Phase 1b trial or new clinical milestones.
- Review the company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K contains none.